Hauptmenü
EURLSSG (European Restless Legs Study Group) met in Munich on 9-
The EURLSSG members meet every year during two days in December in Munich to exchange ideas and and present new results. Members are European researchers and clinicians interested in RLS. The United States are usually represented by Professor Richard P. Allen from Baltimore, MD, who is RLS specialist doing mostly iron research. EARLS was represented by Mrs Joke Jaarsma and Mr Sten Sevborn.
The 2011 meeting was sponsored by Roche (Madopark®/Restex®), Mundipharma (Targiniq® och OxyNorm®), Pfizer (Lyrica® och Neurontin® ), UCB (Neupro®), Vifor Pharma (Ferinject® och Venofer®) and XenoPort (Horizant®).
Unfortunately the two companies selling most RLS medicines -
The program featured 28 lectures, brief 5-
Some of the highlights:
Prevalence in new studies invariably points to high incidence of RLS
RLS is not related to increased mortality
Prevalence differencies between countries cannot be explained by genetics only; a lifestyle study is called for (e.g. influence of nutrients and sesonal variability)
Hypoxia (oxygen deficit) in calves muscels could be related to RLS. Futher study will be done.
RLS is characterized by:
dopamine increase (PLMS's)
glutamate increase (hyperaraousal)
MRI scans can pick up ferritin-
Botulinum toxin (Botox®), was experimentally tested on RLS patients but was not found to be effective
Irone: 500 mg ferrocarboxymaltose had a rapid and immediate effect on RLS symptoms within days